| 摘要 |
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: claimed invention relates to novel compounds of formula 1: or its pharmaceutically acceptable salt; in which each R1 and R8 independently represents H or hydroxyl; each R2 and R9 independently represents H or hydroxyl; R5 represents H; each R3, R4, R6, R7, R13 and R14 independently represents H; or R1 and R2, taken together, form =O; or R4 and R5, taken together form double bond; or R5 and R6, taken together form double bond; R10 and R11, taken together form double bond; R12 represents H, alkyl, hydroxyl, aralkyl, halogenalkyl, alcoxyl,- -[(W)- N(R21)C(O)]qR21, -[(W)-N(R21)SO2]qR21, -[(W)-O]qR21 or -[(W)-N(R21)]qR21; where each W independently represent bivalent alkyl or aralkyl radical, and q is equal 1, 2, 3 or 4; each R15, R16 and R17 independently represent H; each R18 and R19 independently represents H; and each R21 independently represents H, alkyl, aryl or aralkyl. Invention also relates to pharmaceutical composition. Claimed invention provides cycloamine analogues which can be applied to counteract phenotypic effects of undesirable activation of Hedgehog pathway, such as acquiring function from Hedgehog, Ptc loss of function or mitigated acquired from function mutations. ^ EFFECT: compounds by claimed invention are especially applicable in cancer treatment. ^ 19 cl, 1 tbl, 28 ex |
